Valerie Morisset
About Valerie Morisset
Valerie Morisset: Executive Vice President, R&D and Chief Scientific Officer
Valerie Morisset holds the title of Executive Vice President of Research & Development and Chief Scientific Officer. She has an extensive career in the pharmaceutical industry, contributing to many significant projects and organizational roles that leverage her expertise in drug development. Her leadership roles have had a profound impact, especially in the realms of pain management, neurology, and other therapeutic areas.
Valerie Morisset's Role in Co-Founding Convergence Pharmaceuticals
Valerie Morisset co-founded Convergence Pharmaceuticals, a drug development company that focuses on novel and differentiated medicines. Her input was crucial in steering the company towards success, resulting in significant advancements in pain management drugs. Convergence Pharmaceuticals was notably sold to Biogen in 2015 for $675 million, marking a milestone achievement in her career.
Professional Experience at Novartis, GSK, Convergence, and Biogen
Valerie Morisset has built a varied and rich professional background by working at globally recognized companies such as Novartis, GSK, Convergence Pharmaceuticals, and Biogen. Her contributions in these organizations have spanned across numerous therapeutic areas including neurology, psychiatry, and gastrointestinal disorders, among others. Her role at Biogen, taken up post the acquisition of Convergence, further cemented her influence in the pharmaceutical sector.
Valerie Morisset's Educational Background and Expertise
Valerie Morisset trained as an electrophysiologist and completed her doctorate at the University of Bordeaux. Her academic foundation equipped her with specialized expertise that she has applied throughout her career in drug development. Her knowledge in electrophysiology has been pivotal to her success in developing treatments for various disorders.
Founding Venture Partner at Bridge Valley Ventures
Valerie Morisset was a founding venture partner at Bridge Valley Ventures. This role allowed her to leverage her extensive industry knowledge to support and guide innovative pharmaceutical ventures. Her involvement in Bridge Valley Ventures highlights her commitment to fostering new opportunities and driving growth within the drug development industry.